iabetes mellitus (DM) and metabolic syndrome frequently result in congestive heart failure (CHF) with either preserved or unpreserved left ventricular (LV) systolic function, independent of coronary atherosclerosis. 1,2 This is because insulin resistance (IR) and impaired glucose metabolism facilitate not only coronary atherosclerosis leading to coronary events, but also myocardial interstitial fibrosis 3 and coronary microangiopathy, 4,5 at least partly through nitric oxide (NO)/superoxide imbalance. 2, 4 In this regard, new-onset DM during medical treatment of hypertensive patients was reported to significantly increase the risk of cardiovascular events, including CHF, during a long-term follow-up period. 6 Therefore, attention should be paid to the influence of cardiovascular agents on glycemic control during prevention of cardiovascular diseases.
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The hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) have been widely prescribed to reduce cardiovascular events, based on the results of several clinical trials in which lower lipid levels were related to lower coronary event rates. [7] [8] [9] Intensive lipid-lowering therapy with atorvastatin (AS) can stop 10 or reverse 11 the further progression of coronary plaques and shows greater prevention of recurrent coronary events after acute coronary syndrome, compared with standard lipid lowering by pravastatin (PS). 9 Thus, the benefit of intensive lipid lowering to prevent coronary events by stabilizing coronary plaques has been established. However, the effects of statin therapy on glycemic control [12] [13] [14] [15] [16] [17] [18] [19] [20] or on the development of CHF have not been fully investigated and remain controversial. We have recently shown that early and long-term treatment with PS eliciting moderate lipid-lowering effects can retard the development of DM and progression of LV diastolic dysfunction, 15 a manifestation of diabetic cardiomyopathy, in a model of spontaneously developing type II DM, the Otsuka Long-Evans Tokushima Fatty (OLETF) rats. 21 However, whether intensive lipid lowering by other statins can exert greater or similar effects remains unknown. Moreover, although adipocytokines [22] [23] [24] have been emerging as factors affecting IR and should play an important role in the development of DM, the effects of statin therapy on them also remain to be studied.
Therefore, in this study, we compared intensive lipid 
Methods

Animals and Experimental Protocol
The study protocol was approved by the institutional Committee for Experimental Animal Care. Thirty-six OLETF rats of 6 weeks of age were divided into 3 groups: untreated (n=12); PS-treated (n=12); and AS-treated (n= 12). Long-Evans Tokushima Otsuka (LETO) rats, which do not develop DM, served as normal controls (n=12). The control-LETO and untreated-OLETF groups were fed standard chow; the PS-treated OLETF rats were fed basal diet plus PS at a dose of 100 mg/kg per day, which yields a plasma level of PS in the clinical range, 25 and the AStreated OLETF rats were fed the basal diet plus AS at mg/kg per day. All animals were maintained at Kagawa University Animal Experiment Centre and housed in pairs in a pathogen-free facility under controlled temperature (23°C) and humidity (55%) with a 12-h artificial lightdark cycle.
At 10, 20 and 30 weeks of age, blood pressure and heart rate were measured, and Doppler echocardiography was performed to measure early (E) and late (A) diastolic peak transmitral velocities and deceleration time (DT) of early diastolic inflow, 5, 15 and fractional shortening of LV diameter. 15 Blood samples were obtained from the right jugular vein after overnight fasting, and an oral glucose tolerance test (OGTT) was performed as described previously. 5, 15 At 30 weeks of age, all rats were killed under deep anesthesia by intraperitoneal injection of sodium pentobarbital (50 mg/kg), and the heart and visceral white adipose tissue (WAT) were excised.
Biochemical Analyses
Blood levels of glucose, total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), and triglycerides (TG) were determined. Plasma levels of leptin, insulin, tumor necrosis factor-(TNF-), and adiponectin were measured with ELISA kits. IR was evaluated based on the product of fasting glucose and insulin concentrations. 26 Plasma NO levels were measured by the Griess reaction using a TCI-NOX1000W (Tokyo Kasei Kogyo, Japan) as the total of NO end-products, nitrite and nitrate (NOx). 27 
Tissue Processing
The LV was isolated and cut perpendicular to the long axis. One section at the mid-ventricular level was fixed with formalin, embedded in paraffin and cut into 4-mthick sections for histomorphometry. The remaining LV and WAT were immediately frozen in liquid nitrogen and stored at -80°C for extraction of total RNA and/or protein.
Histomorphometry
The wall thickness and degree of perivascular fibrosis of intramyocardial coronary arteries were assessed with Azan-Mallory stain at ×400 magnification. 15 We obtained the wall-to-lumen ratio (medial thickness compared with luminal diameter) and the ratio of the area of perivascular fibrosis to the vascular cross-sectional area in 5-10 crosssections of arteries between 30 and 200 m in diameter in each heart.
Real-Time Reverse Transcription (RT) Polymerase Chain Reaction (PCR)
LV Total RNA was extracted from 0.1 g LV as previously described. 15 The concentration of RNA was measured and an 8-l aliquot (0.2 g/ l) of total RNA was used to synthesize cDNA using a First-Strand cDNA Synthesis Kit (Amersham Biosciences, USA). RT-PCR was performed to quantify the expressions of glyceraldehyde-3-phosphate-dehydrogenase (GAPDH), transforming growth factor (TGF)-1 and monocyte chemoattractant protein (MCP)-1 with an ABI Prism 7000 system. We used a TaqMan Rodent GAPDH Control Reagents VIC™ Prove Kit for GAPDH and Assay-on-Demand Gene Expression Products Kits for TGF-1 and MCP-1 (Applied Biosystems, USA) using the primer sequences and PCR protocols designed by the manufacturer. Adipose Tissue Total RNA was extracted from 0.1 g WAT, and 8-l aliquots containing 0.2 g/ l RNA were used to synthesize cDNA using the First-Strand cDNA Synthesis Kit. Real-time RT-PCR was performed to quantify the expression of adiponectin using the Roche LightCyclerFast Start DNA SYBR Green I kit (Roche Diagnostics, Germany) with a Roche LightCycler system according to the manufacturer's instructions. The primers for the forward reaction were 5'-ACCCAGGAGATGCTG-3' (rat adiponectin cDNA, 233-247 nt), and for the reverse reaction, 5'-ACCTGGAGCCAGACTTGGTC-3' (rat adiponectin cDNA, 622-641 nt). 28 We standardized adiponectin mRNA expression to that of GAPDH. 29 
Western Blot Analysis
The frozen LV tissue was homogenized in a lysis buffer containing a protease inhibitor and centrifuged. The protein concentration of supernatants was determined using the Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, CA). The cytosolic protein (30 g) was separated and transferred to a Nitrocellulose membrane (Bio-Rad Laboratories). The blot was incubated with primary polyclonal antibody (1:1,000) against eNOS (Cell Signaling Technology, Inc) in phosphate-buffered saline-Tween containing 5% fat-free milk, probed with anti-rabbit HRP-linked secondary antibody (1:2,000), and detected by the ECL plus Western Blotting Detection System (Amersham Biosciences). 15 
Statistical Analysis
Data are expressed as mean ± SD. Differences in incidence and measured values among the 4 groups were analyzed by chi-square statistics and ANOVA, respectively, followed by all pair-wise comparisons by Student-Neuman-Keul test. A level of p<0.05 was considered statistically significant.
Results
Body Weight and Food Intake
As shown in Table 1 , the body weight and food intake were greater in all OLETF groups than in the control-LETO group from 10 weeks of age. The hyperphagia was limited only in the PS-treated group, and obesity was suppressed more in the PS-treated than in the AS-treated group throughout the observation period.
Plasma Lipid Levels
The untreated-OLETF showed progressive elevation of TG levels with similar TC and slightly increased HDL-C levels, as compared with the control-LETO rats throughout the observatiostudy. AS exerted much greater lipid-lowering effects, especially TG lowering, than PS (Table 1) . Thus, the same doses of AS and PS given to the rats achieved intensive and moderate lipid lowering, respectively.
Glucose Metabolism
Both fasting insulin and glucose levels, and therefore their product, were progressively increased in all OLETF groups as compared with the LETO group. The progression of IR was significantly limited in the PS-treated group, but not in the AS-treated OLETF group (Table 2) . Fig 1 compares the results of OGTT, in which DM, pre-DM, and normal glucose tolerance were defined according to the American Diabetic Association threshold as in our previous studies. 5, 15 Although the untreated-OLETF rats exhibited progressive glucose intolerance, none of the PStreated OLETF rats were diabetic at 20 weeks, and only 17% of them were diabetic at 30 weeks. In contrast, 33% and 75% of the AS-treated group were diabetic at 20 and 30 weeks, respectively. Thus, although new-onset DM was significantly prevented by the moderate lipid-lowering effect of PS, the intensive lipid-lowering with AS did not either retard or facilitate progressive glucose intolerance.
Adiponectin mRNA Expression in Adipose Tissue
Adiponectin mRNA expression in WAT at 30 weeks was higher in the PS-treated OLETF group than in the other OLETF groups or in the control-LETO group (Fig 2) .
Plasma Levels of Adipocytokines
As summarized in Table 3 , the plasma leptin level was elevated in the untreated-OLETF group compared with the control-LETO rats. However, the elevation was significantly attenuated by PS at all ages, whereas in the AS-treated OLETF it gradually elevated to a level similar to that in the untreated-OLETF at 30 weeks. The plasma adiponectin level, which was significantly higher from 10 weeks in all OLETF groups than in the LETO group, tended to gradually decrease in all OLETF groups. However, PS, but not AS, significantly attenuated the decrease of adiponectin until 30 weeks. TNF-concentration significantly elevated in untreated-OLETF compared with the control-LETO rats at 30 weeks, and was attenuated only in the PS-treated group (Table 3) .
Cardiac eNOS Expression and Plasma NO Concentration
Although the cardiac eNOS protein expression at 30 weeks was upregulated in both of the treated-OLETF groups, the extent of the increase was 1.8-fold greater in the PS-treated group than in the AS-treated group (Fig 3) . The plasma NOx in the untreated-OLETF group were significantly lower than that in the control-LETO group at 20 and 30 weeks ( Table 3 ). The decrease in NOx concentration was prevented until 30 weeks in the PS-treated group only.
TGF-1 and MCP-1 mRNA Expressions in LV
Both TGF-1 and MCP-1 mRNA expressions in the LV at 30 weeks were significantly increased in the untreated-OLETF rats compared with the control-LETO rats (Fig 4) , and was significantly inhibited by PS, but not by AS.
Coronary Arterial Remodeling
Fig 5A compares representative sections of coronary arteries at 30 weeks. The coronary arterial wall was thickened in the untreated-OLETF group with greater perivascular fibrosis as compared with the control-LETO group. Medial wall thickening quantified as the increase in the wall-to-lumen ratio was suppressed by both statins (Fig 5B) , but perivascular fibrosis was limited in the PS-treated group (Fig 5C) .
Hemodynamics and LV Function
Mean blood pressure and heart rate were similar among the 4 groups at any age. Fig 6 compares representative LV inflow recordings at 30 weeks. Compared with the control-LETO rats, the untreated OLETF group exhibited a reduced peak E velocity and slowed deceleration, both of which were restored in the PS-treated group. However, the AStreated group showed a similar pattern to that of the untreated-OLETF group. In the untreated-OLETF group, DT was prolonged from 20 weeks and E/A was reduced at 30 weeks, both of which were restored by the moderate lipid lowering with PS but not by the intensive lipid lowering with AS. Percent fractional shortening of LV diameter was similar among the 4 groups (Table 4) . 
Discussion
In the present study, using a rat model of spontaneously developing type II DM, we demonstrated that the beneficial effects of moderate lipid lowering by PS on both glucose intolerance and LV diastolic dysfunction were associated with preferable adipocytokine profiles and reduced cardiac expressions of oxidative stress-sensitive factors. In contrast, long-term intensive lipid lowering by AS neither had these effects nor retarded the progression of IR or LV diastolic dysfunction in this model.
OLETF Rats as a Model of NO Shortage
This study confirmed that the OLETF rats exhibit progressive IR, hypertriglyceridemia, obesity, progressive increases of leptin and TNF-, and reduction of adiponectin concentrations. These metabolic and adipocytokine abnormalities were associated with coronary perivascular fibrosis, which we had previously reported to be responsible for impaired coronary flow reserve 4 and diastolic LV dysfunction. 5 This model demonstrated overexpressions of TGF-1 and MCP-1 in the LV in our previous study, 15 similar to rats with endothelial dysfunction induced by chronic inhibition of eNOS, 25 which suggests that local shortage of NO might also contribute to the overexpression of these redox-sensitive cytokines in the present model.
eNOS as the Target of Statins
Cardiac eNOS was found to be upregulated in both statin-treated groups at 30 weeks in the present study, which agrees with the results of previous studies showing enhanced expression of eNOS by statins, 15, 25, 30, 31 and suggests that both statins contribute to the limited thickening of the coronary arterial wall. Several mechanisms have been proposed for the upregulation of eNOS by statins, and include cholesterol-independent, but isoprenoid-dependent, intracellular processes at both the transcriptional 32 and post-transcriptional 30 levels.
Unexpectedly, in the present study, eNOS upregulation at 30 weeks was 1.8-fold greater in the PS-treated group than in the AS-treated group. This spontaneous DM model is known to demonstrate increased eNOS expression at an early stage, 20 weeks, 33 but not after 30 weeks. 15 Therefore, although AS likely upregulated eNOS expression more inthe earlier stages, as indicated by the preserved NOx at 20 weeks, the intracellular mechanisms for statin-induced eNOS upregulation were also limited in the AS-treated group at 30 weeks, when the majority of the rats were already diabetic and exposed to elevated levels of oxidative stress.
Moreover, the progressive reduction of the plasma NOx concentration seen in the untreated-OLETF was counteracted by PS-treatment, but not by AS-treatment. It is known that eNOS availability is impaired in the hyperglycemic state because of elevated asymmetric dimethylarginine, 34 an endogenous competitive eNOS inhibitor, and of reduced tetrahydrobiopterin, 35 a cofactor for eNOS. These abnormalities would impair the availability of eNOS, resulting in areduced plasma NOx concentration in the untreated-and AS-treated OLETF rats, which were diabetic at 30 weeks. These observations appear to be consistent with a previous clinical report that intensive lipid lowering by AS does not improve endothelial function in patients with overt type II DM. 36 The greater upregulation of eNOS and prevention of hyperglycemia by the moderate lipid lowering with PS as compared with the intensive lipid lowering by AS would normalize the NO-superoxide balance and inhibit redox sensitive signaling pathways, which might contribute to the greater attenuation of vascular wall overexpression of proinflammatory and proliferative cytokines causing perivascular fibrosis.
Mechanisms for the Differential Effects of Statin Therapy on DM Development
Hypothetical mechanisms for the prevention of newonset DM by statin include reduction of TG and improved endothelial function. 12 In the present study, AS showed strong TG-lowering effects, but did not ameliorate glucose tolerance, so this is therefore unlikely to be the mechanism. As for endothelial function, polymorphisms of eNOS are associated with susceptibility of IR in patients 37 and partial gene deletion of eNOS predisposes to high-fat-diet-induced IR in animals, 38 suggesting a role for eNOS activity in the preservation of insulin sensitivity. Therefore, the greater NO availability in the moderate rather than in the intensive lipid-lowering group could also causally relate to the difference in the preventive effect on DM development, although impaired NO availability is generally regarded as a result of DM. 2 It has been reported that short-term (3 weeks) treatment with AS at lower doses (25 and 50 mg/kg per day) dosedependently improved insulin sensitivity as assessed by euglycemic hyperinsulinemic clamp in another animal model of IR. 17 Those researchers attributed the insulin sensitization to enhanced glucose uptake in skeletal muscle because of increased insulin-stimulated phosphorylation of Akt/PKB. 17 Therefore, it is possible that AS at 100 mg/kg per day might have also transiently improve insulin sensitivity during the early phase of treatment and that the improvement in the IR index at the age of 10 weeks (4 weeks' treatment) in the intensive lipid-lowering group was partially attributable to these mechanisms. However, our study results suggest that long-term treatment with even higher dose of AS does not necessarily result in persistent enhancement of glucose uptake by tissues. In fact, it has been reported that AS even impaired insulin signaling and glucose uptake in adipocytes. 20 The present study suggests another novel mechanism for the prevention of DM by statin therapy, based on modification of the adipocytokine profile, including prevention of leptin elevation or improvement of leptin resistance, and enhanced expression of adiponectin.
Leptin suppresses appetite and improves insulin sensitivity unless leptin resistance exists. 22 The OLETF rats exhibit leptin resistance, 26 which was confirmed in this study as elevated leptin levels despite hyperphagia and obesity in the untreated OLETF. Leptin level was suppressed at 30 weeks only in the PS-treated OLETF, which showed less food intake and body weight compared with the untreated and AS-treated groups. Because the direct anorexic effect of PS at this dose was negated in our previous study, 15 this results implies improved hyperphagia and obesity because of improved leptin resistance in the PS-treated group. In fact, the leptin concentration at 30 weeks had a significant positive correlation with the IR index (r=0.57, p<0.05) when all treatment groups of OLETF rats were combined and analyzed.
Adiponectin increases insulin sensitivity by activating insulin signaling and glucose uptake. 24 This cytokine is secreted by mature adipocytes, and a recent study has demonstrated that AS prevents maturation of pre-adipocytes but PS does not, 20 which implies a different impact of the 2 statins on adipocytes. In the present study, the expression of adiponectin mRNA in WAT was enhanced in the PStreated group but not in the AS-treated group at 30 weeks. Notably, the adiponectin level tended to be elevated in the PS-treated group compared with the other groups as early as 10 weeks of age, and dissimilarly to other groups there was no further decrease from 20 weeks to 30 weeks, and this was accompanied by slowed progression of IR in this group. This trend may suggest a causal relation of the preservation of adiponectin to the retarded onset of DM in the PS-treated group. In the present study, when all groups of treated OLETF rats were combined, the adiponectin concentration at 30 weeks exhibited a significant negative correlation with the IR index (r=-0.48, p<0.05). Thus, it is possible that both improved leptin resistance, shown as lowered leptin concentrations, and a limited decrease in adiponectin may also have contributed to the prevention of progressive IR by statins.
Study Limitations
First, we used different agents to achieve different magnitudes of lipid lowering, as in previous clinical studies. 9, 10 In this regard, neither of the strong statins, rosuvastatin or AS, affected IR in patients with metabolic syndrome when used at moderate lipid-lowering doses. 16 Similarly, it was shown that short-term treatment with lower doses of AS improved insulin sensitivity in Zucker obese rats. 17 Therefore, future studies are necessary to elucidate which of these differences (ie, agents or the intensity of lipid-lowering effects) plays a central role in the present findings. Such studies should include comparison of various doses of these statins or other statins with intermediate or even stronger lipid-lowering effects, with regard to the impact on progressive IR. Second, while it is not possible to directly compare the bioequivalence of drug doses in humans and rats, 100 mg/kg per day of PS is known to provide a plasma concentration in the clinical range. 25 On the other hand, the same dose of AS used in the present study was higher than the 50 mg/kg per day reported to result in a slightly higher concentration than that achieved by the maximum approved dose of AS (80 mg/day) in patients. 17 Although we did not specifically assess adverse effects, the AS-treated rats did not show a significant loss of appetite or delayed weight gain as compared with the PS-treated rats, or deterioration of LV function as compared with the untreated-OLETF rats. Thus, direct toxicity of this dose of AS was unlikely. Third, although enhanced adiponectin expression in WAT and preserved adiponectin levels by moderate lipid lowering with PS, but not by intensive therapy with AS, were shown, the precise reason for the differences remains unknown. Fourth, despite the differences in the effects on IR, which would influence hemodynamics, our study failed to show significant differences in mean blood pressure and heart rate among the groups. Studies using larger number of rats and more strictly controlled measurements might reveal such effects. Lastly, we did not investigate glucose utilization or uptake in the liver, skeletal muscles 17 or adipose tissue, 20 which may also be targets of statins in preventing DM.
Clinical Implications
New-onset DM was shown to negatively impact on the long-term event-free survival of hypertensive patients in a study in which CHF was also included in the cardiovascular events. 6 In that respect, in a trial enrolling survivors of acute myocardial infarction, the subgroup with DM was shown to develop CHF more frequently than the non-diabetic patients, probably because of LV diastolic dysfunction secondary to the alteration of myocardial tissue properties rather than because of classic LV remodeling accompanying LV dilatation. 39 PS treatment was associated with a 30% reduction of new-onset DM in a primary prevention trial, 12 whereas the intensive lipid lowering by AS resulted in even worse glycemic control compared with moderate lipid lowering by PS in survivors of acute coronary syndromes, 14 and hyperglycemia at admission 40 or persistent hyperglycemia in the acute phase 41 of myocardial infarction negatively impacts on the in-hospital outcome of patients following coronary intervention. Similarly, clinical studies in Japan report the superiority of PS to AS in terms of glycemic control in both diabetic 18 and non-diabetic patients. 19 There is no direct clinical evidence that prevention of new-onset DM by statins can indeed improve survival by preventing CHF, including diastolic dysfunction. Nevertheless, the results of the present study, taken together with previous reports, imply a role for moderate lipid lowering by PS, especially in stable or stabilized patients whose long-term survival will be best improved by preventing DM rather than immediate plaque stabilization by intensive lipid lowering.
